Immuron Q3 FY23 Business Update Presentation

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has released its Q3 FY23 Investor Presentation, highlighting significant sales growth. For the two weeks ending April 14, 2023, worldwide sales reached A$320,000, representing 37% of the entire Q3 FY23 total of A$875,000. Year-to-date sales for FY23 until April 14 amounted to A$1,779,000, marking a remarkable 233% increase compared to A$534,000 for the same period in FY22. The company is focusing on its oral immunotherapeutic products for gut-mediated diseases. Investors are invited to participate in a webinar hosted by CEO Steven Lydeamore for further insights.

Positive

• Worldwide sales for two weeks (April 1-14, 2023) totaled A$320,000, 37% of Q3 FY23.
• Year-to-date sales (FY23) increased to A$1,779,000, up 233% from A$534,000 in FY22.

Negative

• None.

MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar to be held today at 11:00 am (AEST).

The Investor Presentation includes the following material information (unaudited):

• Worldwide sales for the two weeks 1 to 14 April 2023 were A$320,000.
  This represents 37% of sales for the whole of Q3 FY23 of A$875,000.
  
• Sales FY23 YTD to 14 April 2023 of A$1,779,000 represents a 233% increase over the corresponding prior period YTD to 14 April 2022 of $534,000.

Investors are invited to join the webcast and Q&A hosted by Immuron CEO Steven Lydeamore.

To register for the webinar, please click on this link:

https://us02web.zoom.us/webinar/register/WN_TpvaXZZ1QDG1FnZdXdtSGA

After registering, you will receive a confirmation email containing information to join the webinar.

A copy of the presentation slide deck is available on the Company’s website.

https://www.immuron.com.au/corporate-presentations/

Approved for release by the CEO.

COMPANY CONTACT:

Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit: http://www.immuron.com

FAQ

What were Immuron's Q3 FY23 sales figures?

Immuron reported worldwide sales of A$320,000 for the two weeks from April 1-14, 2023, amounting to 37% of the total Q3 FY23 sales of A$875,000.

How much did Immuron's sales increase year-to-date in FY23?

For FY23 year-to-date up to April 14, 2023, Immuron's sales reached A$1,779,000, a 233% increase compared to A$534,000 for the same period in FY22.

When is Immuron's investor presentation webinar?

The investor presentation webinar is scheduled for April 19, 2023, at 11:00 am (AEST).

Who is the host of Immuron's investor presentation webinar?

The webinar will be hosted by Immuron's CEO, Steven Lydeamore.

Where can I find Immuron's Q3 FY23 Investor Presentation slides?

A copy of the presentation slide deck is available on Immuron's website.